Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Article in English | MEDLINE | ID: mdl-38294505

ABSTRACT

Smoking is one of the main causes of death in the world. Cigarette use is related with various components of metabolic syndrome (e.g., insulin resistance, raised blood pressure, dyslipidemia, oxidative stress, inflammation state) and psychiatric disorders. This study was conducted to determine the effect of crocin (Cro) supplementation on nicotine dependence, anxiety, depression, and metabolic indices in smokers. A total of 50 smokers were selected and randomly categorized into two groups (crocin and placebo). The intervention group received crocin (30 mg per day; n = 25) and placebo (containing Avicel; n = 25) once a day. The primary (nicotine dependence, depression, and anxiety inventory) and secondary (metabolic indices) outcomes were assessed at the start of the intervention and after the 3 months. Multiple linear regression models were used to assess the treatment effects on the outcomes adjusting for confounding variables. The primary outcome results such as nicotine dependence, depression, and anxiety inventory did not have a significant difference among the intervention groups (P > 0.05). Also in the secondary outcomes, fasting plasma glucose (FPG), insulin, and homeostasis model of assessment-insulin resistance (HOMA-IR) levels did indicate a significant difference by Cro intervention (ß - 3.27 mg/dL; 95% CI, - 5.23, - 1.31; P = 0.002; ß - 0.76 µIU/mL; 95% CI, - 1.38, - 0.15; P = 0.01; ß - 0.18; 95% CI, - 0.29, - 0.07; P = 0.002), respectively. There were also significant reductions in serum levels of high-sensitivity C-reactive protein (hs-CRP) (ß - 0.72 mg/L; 95% CI, - 1.37, - 0.07; P = 0.03), compared with the placebo. Cro intake may have favorable effects on the level of FPG, insulin, HOMA-IR, and hs-CRP in smokers. However, due to the small sample size and limited scientific reports on smokers, further studies are necessary. ClinicalTrial.gov Identifier: IRCT20170420033551N11.

2.
Environ Sci Pollut Res Int ; 30(52): 112071-112085, 2023 Nov.
Article in English | MEDLINE | ID: mdl-37828260

ABSTRACT

Drug abuse has a high prevalence worldwide and causes many health-related disorders. There are limited human exposure studies on establishing lead exposure levels and their propensity for drug addiction. In the present study, blood samples were tested for lead (Pb) concentrations in illicit drug users together with the related symptoms in comparison with control group of non-drug users. The study was performed on 250 volunteers divided equally in four drug groups, namely, opioids, hashish, methadone, and methamphetamine, and one control group of non-drug users. Participants were recruited from drug addiction clinics and camps in Kashan city, Iran, who were using drugs continuously for more than 1 year. Control group was recruited from companions of the patients with no drug use history. In the investigated groups of drug users, the highest blood-lead level (BLL) concentrations were observed in the opioid group (mean 37.57 µg/dL) with almost 3.7 times higher than in the control group (mean 3.39 µg/dL). In the methamphetamine group, type of occupation had the significant association with BLL concentrations. The positive correlation was revealed in the opioid and methadone groups for BLL concentrations and the duration of drug usage. In the opioid group, the highest BLL concentrations were observed among users who used both methods of drug use: smoking and eating. Also, several behavioral and life-style factors were identified which influence the blood-lead concentration in the drug users. The results of our study revealed that the BLL concentrations in investigated drug users' groups were significantly higher than in the control group (P < 0.001). That can be related with the Pb contents in illicitly used drugs. Apart other adverse health effects, long-term illicit drug use might cause to lead poisoning.


Subject(s)
Illicit Drugs , Methamphetamine , Substance-Related Disorders , Humans , Lead , Analgesics, Opioid , Iran , Substance-Related Disorders/epidemiology , Methadone
3.
Am J Drug Alcohol Abuse ; 48(3): 311-320, 2022 05 04.
Article in English | MEDLINE | ID: mdl-35404725

ABSTRACT

Background: Addiction is associated with decreased activity of the prefrontal networks, especially dorsolateral prefrontal cortex (DLPFC).Objective: This study examined the effectiveness of transcranial direct current stimulation (tDCS) over DLPFC in combination with Matrix Model psychotherapy in the alleviation of craving and cognitive improvement of participants with methamphetamine use disorder.Methods: In a randomized and sham-controlled trial, 60 male participants were assigned to Matrix psychotherapy only, sham tDCS plus Matrix, or active tDCS plus Matrix. Sixteen sessions of 20-min anodal (2 mA over F3 for targeting the left DLPFC) or sham tDCS along were administered in the outpatient setting. Pre- and post-intervention craving, executive functioning, and working memory were assessed using the Obsessive-Compulsive Drug Use Scale, Wisconsin Card Sorting Test, and Wechsler Memory Scale, respectively. One month following the interventions relapse was investigated by urine drug screen or interview.Results: In comparison with sham tDCS (n = 12) and Matrix psychotherapy only group (n = 13), the active tDCS group (n = 15) showed more reduction in craving (p<.05, η2 = .21). Auditory and visual memory (Wechsler) and true answers and false answers (WCST) significantly improved in the active tDCS group (η2 = .18, η2 = 12, η2 = 03, η2 = .02, respectively) but not in the other groups. Relapse rates did not significantly differ between groups (p = .17). A significant correlation was found between craving reduction and cognitive functioning in the active tDCS group.Conclusion: The combination of Matrix Model psychotherapy and tDCS may an effective therapy for cognitive improvement and craving in participants with methamphetamine use disorder.Clinical Trials Registry: This study was registered at the Iranian Registry of Clinical Trials (IRCT20161026030510N3).


Subject(s)
Methamphetamine , Transcranial Direct Current Stimulation , Cognition , Craving/physiology , Double-Blind Method , Humans , Iran , Male , Prefrontal Cortex/physiology , Recurrence
4.
Iran J Psychiatry ; 16(1): 21-29, 2021 Jan.
Article in English | MEDLINE | ID: mdl-34054979

ABSTRACT

Objective: The aim of the present study was to determine the efficacy of acceptance and commitment therapy (ACT) compared to cognitive-behavioral therapy (CBT) on anger and interpersonal relationships among male students. Method : In the present study, several universities were selected from the public universities in Tehran province, based on random cluster sampling. Then, 400 students from selected universities were selected randomly and Aggression Questionnaire (AGQ) was administered on them. After collecting information, among the participants who gained scores higher than the average, 30 were selected based on the lottery and randomly (sorting their names in alphabetical order and randomly selecting them) and then were placed randomly in ACT (n = 15) and CBT (n = 15) groups. Also, the Fundamental Interpersonal Relation Orientation- Behavior (FIRO-B) and Aggression Questionnaire (AGQ) was performed on both groups before and after intervention. Results: The results indicated that at the end of treatment, there was a significant decrease in the degree of anger among the participants and a significant improvement in all subscales of interpersonal relationships. Also, a significant difference was found between the 2 groups of ACT and CBT in terms of anger changes. Considering that the anger changes in the ACT group were higher, it can be concluded that the ACT group had more changes than the CBT group, but there was no significant difference between the 2 groups of ACT and CBT in terms of FIRO-B subscales. Conclusion: In some cases, such as anger, ACT has a better effect than CBT, and in others, such as interpersonal problems, it is as effective as CBT.

5.
Phytother Res ; 33(10): 2714-2725, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31359519

ABSTRACT

Patients under methadone maintenance treatment (MMT) programs are susceptible to several complications including metabolic and clinical disorders. This study was designed to determine the effect of crocin supplementation on mental health parameters and metabolic profiles in subjects under MMT. The current randomized, double-blind, placebo-controlled, clinical trial was conducted among 53 patients under MMT to receive either 15 mg/day of crocin (n = 26) or placebo (n = 27) twice a day for 8 weeks. Crocin administration significantly decreased Beck Depression Inventory score (P = 0.01) and Beck Anxiety Inventory score (P = 0.008) compared with the placebo. In addition, crocin administration resulted in a significant reduction in fasting glucose (P = 0.003), insulin levels (P = 0.01), insulin resistance (P = 0.008), triglycerides (P = 0.001), very low-density lipoprotein (P = 0.001), total cholesterol levels (P = 0.03), and a significant increase in insulin sensitivity (.003) compared with the placebo. Additionally, crocin intake was associated with a significant reduction in high-sensitivity C-reactive protein (p < .001) and malondialdehyde (P = 0.001) and a significant rise in total antioxidant capacity levels (P = 0.01) compared with the placebo. The findings of this clinical trial indicate that taking crocin for 8 weeks by patients under MMT had beneficial effects on their mental health and improved their metabolic profiles.


Subject(s)
Carotenoids/administration & dosage , Methadone/therapeutic use , Opioid-Related Disorders/rehabilitation , Adult , Blood Glucose/analysis , Carotenoids/pharmacology , Dietary Supplements , Double-Blind Method , Female , Humans , Insulin Resistance , Lipids/blood , Male , Middle Aged , Opioid-Related Disorders/metabolism , Opioid-Related Disorders/psychology
6.
Asian J Psychiatr ; 37: 146-153, 2018 Oct.
Article in English | MEDLINE | ID: mdl-30237112

ABSTRACT

OBJECTIVE: This survey was conducted to investigate the prevalence of various psychiatric disorders among children and adolescents aged 6-18 years in urban areas of Tehran. METHODS: In the study, which was done with random sampling method, 2095 children and adolescents in the range seniors aged 6-18 years, have been studied and based on Persian version of K-SADS-PL, we reviewed the psychiatric disorders related to them. RESULTS: The overall prevalence of psychiatric disorders in children and adolescents was 28.2%. The most commonly diagnosed disorders were anxiety disorders (21.9%), followed by behavioral disorders (9.6%). CONCLUSION: According to the results, 28.2% of the children and adolescents in Tehran province had psychiatric disorders, that is with increasing rate, compared with similar studies. Therefore, as a public health policy, the necessary tools for identifying, preventing and treating psychiatric disorders in children and adolescents should be considered in Tehran.


Subject(s)
Mental Disorders/epidemiology , Urban Population/statistics & numerical data , Adolescent , Anxiety Disorders/epidemiology , Attention Deficit and Disruptive Behavior Disorders/epidemiology , Child , Comorbidity , Cross-Sectional Studies , Female , Humans , Iran/epidemiology , Male , Mood Disorders/epidemiology , Prevalence
SELECTION OF CITATIONS
SEARCH DETAIL
...